The impact of Aβ-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in alzheimer's disease-like transgenic mice

Neuroscience

Volumn 121, Issue 2, 2003, Pages 421-432

  Hu, L ^a,b   Wong, T P ^a   Cote S L ^a   Bell, K F S ^a   Cuello, A C ^a  

^a MCGILL UNIVERSITY   (Canada)

^b JILIN UNIVERSITY   (China)

Author keywords

Amyloid plaque; Amyloid precursor protein; Pre synaptic bouton; Presenilin 1; Synaptophysin; Vesicular acetylcholine transporter

Indexed keywords

AMYLOID BETA PROTEIN; SYNAPTOPHYSIN; VESICULAR ACETYLCHOLINE TRANSPORTER; ACETYLCHOLINE; AMYLOID PRECURSOR PROTEIN; CARRIER PROTEIN; MEMBRANE PROTEIN; NEUROPEPTIDE; PRESENILIN 1; VESICULAR AMINE TRANSPORTER;

ALZHEIMER DISEASE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CHOLINERGIC SYSTEM; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DENSITY; ELECTRON MICROSCOPY; FRONTAL CORTEX; IMMUNOREACTIVITY; MOUSE; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; PARTICLE SIZE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; SENILE PLAQUE; STATISTICAL SIGNIFICANCE; TRANSGENIC MOUSE; ANALYSIS OF VARIANCE; ANIMAL; BRAIN CORTEX; CELL COUNT; COMPARATIVE STUDY; DISEASE MODEL; FRONTAL LOBE; GENETICS; HIPPOCAMPUS; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; METABOLISM; NEUROPIL; SYNAPTOSOME; ULTRASTRUCTURE;

ACETYLCHOLINE; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; CELL COUNT; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; FRONTAL LOBE; HIPPOCAMPUS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON; NEUROPEPTIDES; NEUROPIL; PRESENILIN-1; PRESYNAPTIC TERMINALS; SENILE PLAQUES; SYNAPTOPHYSIN; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS;

EID: 0141644282     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(03)00394-4     Document Type: Article

References (104)

1. Baladi J.F., Bailey P.A., Black S., Bouchard R.W., Farcnik K.D., Gauthier S., Kertesz A., Mohr E., Robillard A. Rivastigmine for Alzheimer's disease Canadian interpretation of intermediate outcome measures and cost implications . Clin Ther. 22:2000;1549-1561.
2. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., Prada C.M., Kim G., Seekins S., Yager D., Slunt H.H., Wang R., Seeger M., Levey A.I., Gandy S.E., Copeland N.G., Jenkins N.A., Price D.L., Younkin S.G., Sisodia S.S. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron. 17:1996;1005-1013.
3. Borchelt D.R., Ratovitski T., van Lare J., Lee M.K., Gonzales V., Jenkins N.A., Copeland N.G., Price D.L., Sicedia S.S. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 19:1997;939-945.
4. Bowen D.M., Benton J.S., Spillane J.A., Smith C.C., Allen S.J. Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients. J Neurol Sci. 57:1982;191-202.
5. Bowen D.M., Smith C.D. Neurotransmitter related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain. 99:1976;459-496.
6. Burns A., Rossor M., Hecker J., Gauthier S., Petit H., Moller H.J., Rogers S.L., Friedhoff L.T. The effects of donepezil in Alzheimer's disease results from a multinational trial . Dement Geriatr Cogn Disord. 10:1999;237-244.
7. Cai X.D., Golde T.E., Younkin S.G. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science. 259:1993;514-516.
8. Catsicas M., Pequignot Y., Clarke P.G. Rapid onset of neuronal death induced by blockade of either axoplasmic transport or action potentials in afferent fibers during brain development. J Neurosci. 12:1992;4642-4650.
9. Chui D.H., Tanahashi H., Ozawa K., Ikeda S., Checler F., Ueda O., Suzuki H., Araki W., Inoue H., Shirotani K., Takahashi K., Gallyas F., Tabira T. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med. 5:1999;560-564.
10. Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A.Y., Seubert P., Vigo-Pelfrey C., Lieberburg I., Selkoe D.J. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature. 360:1992;672-674.
11. Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., Johnson-Wood K., Lee M., Seubert P., Davis A., Kholodenko D., Motter R., Sherrington R., Perry B., Yao H., Strome R., Lieberburg I., Rommens J., Kim S., Schenk D., Fraser P., St George H.P., Selkoe D.J. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med. 3:1997;67-72.
12. Collerton D. Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience. 19:1986;1-28.
13. Collie A., Maruff P. The neuropsychology of preclinical Alzheimer's disease and mild cognitive impairment. Neurosci Biobehav Rev. 24:2000;365-374.
14. Côté S., Ribeiro-da-Silva A., Cuello A.C. Current protocols for light microscopy immunocytochemistry. Cuello A.C. Immunohistochemistry II. 1993;147-168 John Wiley and Sons, Chichester.
15. Cummings J.L., Vinters H.V., Cole G.M., Khachaturian Z.S. Alzheimer's disease etiologies, pathophysiology, cognitive reserve, and treatment opportunities . Neurology. 51:1998;S2-17.
16. Dai J., Buijs R.M., Kamphorst W., Swaab D.F. Impaired axonal transport of cortical neurons in Alzheimer's disease is associated with neuropathological changes. Brain Res. 948:2002;138-144.
17. Davies C.A., Mann D.M., Sumpter P.Q., Yates P.O. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci. 78:1987;151-164.
18. Davies P., Maloney A.J.F. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 2:1976;1403.
19. Davis K.L., Mohs R.C., Marin D., Purohit D.P., Perl D.P., Lantz M., Austin G., Haroutunian V. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 281:1999;1401-1406.
20. DeKosky S.T., Harbaugh R.E., Schmitt F.A., Bakay R.A., Chui H.C., Knopman D.S., Reeder T.M., Shetter A.G., Senter H.J., Markesbery W.R. Cortical biopsy in Alzheimer's disease diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations: Intraventricular Bethanecol Study Group . Ann Neurol. 32:1992;625-632.
21. DeKosky S.T., Ikonomovic M.D., Styren S.D., Beckett L., Wisniewski S., Bennett D.A., Cochran E.J., Kordower J.H., Mufson E.J. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 51:2002;145-155.
22. DeKosky S.T., Scheff S.W. Synapse loss in frontal cortex biopsies in Alzheimer's disease correlation with cognitive severity . Ann Neurol. 27:1990;457-464.
23. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J., Younkin S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 383:1996;710-713.
24. Feldman H., Gauthier S., Hecker J., Vellas B., Subbiah P., Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 57:2001;613-620.
25. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates. 1997;Academic Press, San Diego.
26. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 373:1995;523-527.
27. Gauthier S. Acetylcholinesterase inhibitors in the treatment of Alzheimer's disease. Expert Opin Invest Drugs. 8:1999;1511-1520.
28. Gauthier S., Bouchard R., Bacher Y., Bailey P., Bergman H., Carrier L., Charbonneau R., Clarfield M., Collier B., Dastoor D. Progress report on the Canadian Multicentre Trial of tetrahydroaminoacridine with lecithin in Alzheimer's disease. Can J Neurol Sci. 16:1989;543-546.
29. Gauthier S., Bouchard R., Lamontagne A., Bailey P., Bergman H., Ratner J., Tesfaye Y., Saint-Martin M., Bacher Y., Carrier L. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease results of a Canadian double-blind, crossover, multicenter study . N Engl J Med. 322:1990;1272-1276.
30. Gauthier S., Feldman H., Hecker J., Vellas B., Emir B., Subbiah P. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Curr Med Res Opin. 18:2002;347-354.
31. Geula C., Mesulam M.M., Saroff D.M., Wu C.K. Relationship between plaques, tangles, and loss of cortical cholinergic fibers in Alzheimer disease. J Neuropathol Exp Neurol. 57:1998;63-75.
32. Giacobini E. The second generation of cholinesterase inhibitors pharmacological aspects . Becker R.E., Giacobini E. I: Cholinergic basis for Alzheimer therapy. 1991;247-262 Birkhäuser, Boston.
33. Giacobini E. Selective inhibitors of butyrylcholinesterase a valid alternative for therapy of Alzheimer's disease? Drugs Aging. 18:2001;891-898.
34. Giacobini E. Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer' disease. J Neural Transm Suppl. 181:(-):2002;187.
35. Giannakopoulos P., Hof P.R., Michel J.P., Guimon J., Bouras C. Cerebral cortex pathology in aging and Alzheimer's disease a quantitative survey of large hospital-based geriatric and psychiatric cohorts . Brain Res Brain Res Rev. 25:1997;217-245.
36. Gilmor M.L., Nash N.R., Roghani A., Edwards R.H., Yi H., Hersch S.M., Levey A.I. Expression of the putative vesicular acetylcholine transporter in rat brain and localization in cholinergic synaptic vesicles. J Neurosci. 16:1996;2179-2190.
37. Gomez-Isla T., Hollister R., West H., Mui S., Growdon J.H., Petersen R.C., Parisi J.E., Hyman B.T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 41:1997;17-24.
38. Grant S.M., Ducatenzeiler A., Szyf M., Cuello A.C. Abeta immunoreactive material is present in several intracellular compartments in transfected, neuronally differentiated, P19 cells expressing the human amyloid beta-protein precursor. J Alzheimers Dis. 2:2000;207-222.
39. Hamos J.E., DeGennaro L.J., Drachman D.A. Synaptic loss in Alzheimer's disease and other dementias. Neurology. 39:1989;355-361.
40. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease progress and problems on the road to therapeutics . Science. 297:2002;353-356.
41. Heinonen O., Soininen H., Sorvari H., Kosunen O., Paljärvi L., Koivisto E., Riekkinen P.J. Sr. Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomenon in Alzheimer's disease. Neuroscience. 64:1995;375-384.
42. Hernandez D., Sugaya K., Qu T., McGowan E., Duff K., McKinney M. Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes. Neuroreport. 12:2001;1377-1384.
43. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy Prada C.M., Eckman C., Younkin S., Hsiao K., Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 4:1998;97-100.
44. Honer W.G., Dickson D.W., Gleeson J., Davies P. Regional synaptic pathology in Alzheimer's disease. Neurobiol Aging. 13:1992;375-382.
45. Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., Kholodenko D., Malenka R.C., Nicoll R.A., Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA. 96:1999;3228-3233.
46. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Ab elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
47. Ikonomovic MD, Mufson EJ, Cochran EJ, Bennett DA, DeKosky ST. Acetylcholinesterase changes in people with mild cognitive impairment: implications for hippocampal plasticity. Soc Neurosci Abstr Program No. 882.6 2002. 5-11-2002.
48. Jahn R., Schiebler W., Ouimet C., Greengard P. A 38,000-dalton membrane protein (p38) present in synaptic vesicles. Proc Natl Acad Sci USA. 82:1985;4137-4141.
49. Juliano S.L., Ma W., Eslin D. Cholinergic depletion prevents expansion of topographic maps in somatosensory cortex. Proc Natl Acad Sci USA. 88:1991;780-784.
50. Kilgard M.P., Merzenich M.M. Cortical map reorganization enabled by nucleus basalis activity. Science. 279:1998;1714-1718.
51. Knowles R.B., Wyart C., Buldyrev S.V., Cruz L., Urbanc B., Hasselmo M.E., Stanley H.E., Hyman B.T. Plaque-induced neurite abnormalities implications for disruption of neural networks in Alzheimer's disease . Proc Natl Acad Sci USA. 96:1999;5274-5279.
52. Ladner C.J., Lee J.M. Pharmacological drug treatment of Alzheimer disease the cholinergic hypothesis revisited . J Neuropathol Exp Neurol. 57:1998;719-731.
53. Lahiri D.K., Farlow M.R., Sambamurti K., Greig N.H., Giacobini E., Schneider L.S. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets. 4:2003;97-112.
54. Lassmann H., Weiler R., Fischer P., Bancher C., Jellinger K., Floor E., Danielczyk W., Seitelberger F., Winkler H. Synaptic pathology in Alzheimer's disease immunological data for markers of synaptic and large dense-core vesicles . Neuroscience. 46:1992;1-8.
55. Levy-Lahad E., Wasco W., Poorkaj P., Romano D.M., Oshima J., Pettingell W.H., Yu C.E., Jondro P.D., Schmidt S.D., Wang K. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 269:1995;973-977.
56. Lippa C.F., Hamos J.E., Pulaski-Salo D., DeGennaro L.J., Drachman D.A. Alzheimer's disease and aging effects on perforant pathway perikarya and synapses . Neurobiol Aging. 13:1992;405-411.
57. Lowe A.W., Madeddu L., Kelly R.B. Endocrine secretory granules and neuronal synaptic vesicles have three integral membrane proteins in common. J Cell Biol. 106:1988;51-59.
58. Luo J.J., Wallace M.S., Hawver D.B., Kusiak J.W., Wallace W.C. Characterization of the neurotrophic interaction between nerve growth factor and secreted alpha-amyloid precursor protein. J Neurosci Res. 63:2001;410-420.
59. Masliah E. Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol Histopathol. 10:1995;509-519.
60. Masliah E., Sisk A., Mallory M., Mucke L., Schenk D., Games D. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F b-amyloid precursor protein and Alzheimer's disease. J Neurosci. 16:1996;5795-5811.
61. Mattson M.P., Cheng B., Culwell A.R., Esch F.S., Lieberburg I., Rydel R.E. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron. 10:1993;243-254.
62. McGeer P.L., Rogers J., McGeer E.G. Neuroimmune mechanisms in Alzheimer disease pathogenesis. Alzheimer Dis Assoc Disord. 8:1994;149-158.
63. McLeod A.L., Krause J.E., Cuello A.C., Ribeiro-da-Silva A. Preferential synaptic relationships between substance P-immunoreactive boutons and neurokinin 1 receptor sites in the rat spinal cord. Proc Natl Acad Sci USA. 95:1998;15775-15780.
64. McLeod A.L., Krause J.E., Ribeiro-da-Silva A. Immunocytochemical localization of neurokinin B in the rat spinal dorsal horn and its association with substance P and GABA an electron microscopic study . J Comp Neurol. 420:2000;349-362.
65. Morris J.C., Storandt M., Miller J.P., McKeel D.W., Price J.L., Rubin E.H., Berg L. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 58:2001;397-405.
66. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice synaptotoxicity without plaque formation . J Neurosci. 20:2000;4050-4058.
67. Mulugeta E., Karlsson E., Islam A., Kalaria R., Mangat H., Winblad B., Adem A. Loss of muscarinic M(4) receptors in hippocampus of Alzheimer patients. Brain Res. 960:2003;259-262.
68. Nalbantoglu J., Tirado-Santiago G., Lahsaini A., Poirier J., Goncalves O., Verge G., Momoli F., Welner S.A., Massicotte G., Julien J.P., Shapiro M.L. Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature. 387:1997;500-505.
69. Navone F., Jahn R., Di Gioia G., Stukenbrok H., Greengard P., De Camilli P. Protein p38 an integral membrane protein specific for small vesicles of neurons and neuroendocrine cells . J Cell Biol. 103:1986;2511-2527.
70. Perry E.K., Johnson M., Kerwin J.M., Piggott M.A., Court J.A., Shaw P.J., Ince P.G., Brown A., Perry R.H. Convergent cholinergic activities in aging and Alzheimer's disease. Neurobiol Aging. 13:1992;393-400.
71. Perry E.K., Tomlinson B.E., Blessed G., Bergmann K., Gibson P.H., Perry R.H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ. 2:1978;1457-1459.
72. Phinney A.L., Deller T., Stalder M., Calhoun M.E., Frotscher M., Sommer B., Staufenbiel M., Jucker M. Cerebral amyloid induces aberrant axonal sprouting and ectopic terminal formation in amyloid precursor protein transgenic mice. J Neurosci. 19:1999;8552-8559.
73. Pickel V.M. Immunocytochemical methods. Heimer L., Robards M.J. Neuroanatomical tract tracing methods. 1981;483-509 Plenum Press, New York.
74. Price D.L., Sisodia S.S. Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci. 21:1998;479-505.
75. Quirion R., Martel J.C., Robitaille Y., Etienne P., Wood P., Nair N.P., Gauthier S. Neurotransmitter and receptor deficits in senile dementia of the Alzheimer type. Can J Neurol Sci. 13:1986;503-510.
76. Ribeiro-da-Silva A., Priestley J.V., Cuello A.C. Pre-embedding ultrastructural immunocytochemistry. Cuello A.C. Immunohistochemistry II. 1993;181-227 John Wiley and Sons, Chichester.
77. Rockwood K., Beattie B.L., Eastwood M.R., Feldman H., Mohr E., Pryse-Phillips W., Gauthier S. A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease. Can J Neurol Sci. 24:1997;140-145.
78. Roghani A., Shirzadi A., Kohan S.A., Edwards R.H., Butcher L.L. Differential distribution of the putative vesicular transporter for acetylcholine in the rat central nervous system. Mol Brain Res. 43:1996;65-76.
79. Scheff S.W., DeKosky S.T., Price D.A. Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol Aging. 11:1990;29-37.
80. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 2:1996;864-870.
81. Selkoe D.J. Amyloid beta-protein precursor new clues to the genesis of Alzheimer's disease . Curr Opin Neurobiol. 4:1994;708-716.
82. Selkoe D.J. Toward a comprehensive theory for Alzheimer's disease hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein . Ann NY Acad Sci. 924:2000;17-25.
83. Semenenko F.M., Bramwell S., Sidebottom E., Cuello A.C. Development of a mouse antiperoxidase secreting hybridoma for use in the production of a mouse PAP complex for immunocytochemistry and as a parent cell line in the development of hybrid hybridomas. Histochemistry. 83:1985;405-408.
84. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., Chi H., Lin C., Li G., Holman K. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 375:1995;754-760.
85. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Bürki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 94:1997;13287-13292.
86. Sudhof T.C., Jahn R. Proteins of synaptic vesicles involved in exocytosis and membrane recycling. Neuron. 6:1991;665-677.
87. Suzuki N., Cheung T.T., Cai X.D., Odaka A., Otvos L. Jr, Eckman C., Golde T.E., Younkin S.G. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 264:1994;1336-1340.
88. Svensson A.L., Alafuzoff I., Nordberg A. Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists. Brain Res. 596:1992;142-148.
89. Tang Y., Mishkin M., Aigner T.G. Effects of muscarinic blockade in perirhinal cortex during visual recognition. Proc Natl Acad Sci USA. 94:1997;12667-12669.
90. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease synapse loss is the major correlate of cognitive impairment . Ann Neurol. 30:1991;572-580.
91. Thompson S.A., Hodges J.R. Mild cognitive impairment a clinically useful but currently ill-defined concept? Neurocase. 8:2002;405-410.
92. Usdin T.B., Eiden L.E., Bonner T.I., Erickson J.D. Molecular biology of the vesicular ACh transporter. Trends Neurosci. 18:1995;218-224.
93. Walaas S.I., Jahn R., Greengard P. Quantitation of nerve terminal populations synaptic vesicle- associated proteins as markers for synaptic density in the rat neostriatum . Synapse. 2:1988;516-520.
94. Wallace W., Ahlers S.T., Gotlib J., Bragin V., Sugar J., Gluck R., Shea P.A., Davis K.L., Haroutunian V. Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation. Proc Natl Acad Sci USA. 90:1993;8712-8716.
95. Wallace W.C., Akar C.A., Lyons W.E. Amyloid precursor protein potentiates the neurotrophic activity of NGF. Brain Res Mol Brain Res. 52:1997;201-212.
96. Wallace W.C., Akar C.A., Lyons W.E., Kole H.K., Egan J.M., Wolozin B. Amyloid precursor protein requires the insulin signaling pathway for neurotrophic activity. Brain Res Mol Brain Res. 52:1997;213-227.
97. Wallace W.C., Lieberburg I., Schenk D., Vigo-Pelfrey C., Davis K.L., Haroutunian V. Chronic elevation of secreted amyloid precursor protein in subcortically lesioned rats, and its exacerbation in aged rats. J Neurosci. 15:1995;4896-4905.
98. Weihe E., Tao-Cheng J.H., Schafer M.K., Erickson J.D., Eiden L.E. Visualization of the vesicular acetylcholine transporter in cholinergic nerve terminals and its targeting to a specific population of small synaptic vesicles. Proc Natl Acad Sci USA. 93:1996;3547-3552.
99. Wiedenmann B., Franke W.W. Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. Cell. 41:1985;1017-1028.
100. Winkler J., Suhr S.T., Gage F.H., Thal L.J., Fisher L.J. Essential role of neocortical acetylcholine in spatial memory. Nature. 375:1995;484-487.
101. Wong T.P., Campbell P.M., Ribeiro-da-Silva A., Cuello A.C. Synaptic numbers across cortical laminae and cognitive performance of the rat during ageing. Neuroscience. 84:1998;403-412.
102. Wong T.P., De Koninck Y., Ribeiro-da-Silva A., Cuello A.C. Synaptic inputs to identified layer V pyramidal neurons of the cerebral cortex in young and aged rats. Soc Neurosci Abstr. 23:1997;1460.
103. Wong T.P., Debeir T., Duff K., Cuello A.C. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J Neurosci. 19:1999;2706-2716.
104. Yesavage J.A., O'Hara R., Kraemer H., Noda A., Taylor J.L., Ferris S., Gely-Nargeot M.C., Rosen A., Friedman L., Sheikh J., Derouesne C. Modeling the prevalence and incidence of Alzheimer's disease and mild cognitive impairment. J Psychiatr Res. 36:2002;281-286.